LGI1-Antibody Encephalitis clinical trials at UCSF
1 research study open to eligible people
LGI1-antibody encephalitis is a brain disorder caused by the immune system attacking healthy cells. UCSF is testing a drug called Satralizumab to see if it helps people with this condition. The study also checks how safe the drug is and how it works in the body.
Showing trials for
(PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
open to eligible people ages 12 years and up
The purpose of this study is to assess the efficacy, safety, PK, and PD of satralizumab in participants with NMDAR and LGI1 encephalitis.
San Francisco, California and other locations
Our lead scientists for LGI1-Antibody Encephalitis research studies include Jeffrey Gelfand.
Last updated: